Back
Adaptimmune Therapeutics PLC Quote, Financials, Valuation and Earnings
Buy
64
ADAP
Adaptimmune Therapeutics PLC
Last Price:
1.19
Seasonality Move:
-1.36%
7 Day Trial
ALL ACCESS PASS
$
7
Adaptimmune Therapeutics PLC Price Quote
$1.19
-0.05 (-4.03%)
(Updated: May 16, 2024 at 6:55 PM ET)
Adaptimmune Therapeutics PLC Key Stats
Buy
64
Adaptimmune Therapeutics PLC (ADAP)
is a Buy
Day range:
$1.13 - $1.27
52-week range:
$0.42 - $2.05
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
4.14
P/B ratio:
7.75%
Volume:
1.4M
Avg. volume:
1.1M
1-year change:
-10.79%
Market cap:
$306.1M
Revenue:
$60.3M
EPS:
$-0.47
How Much Does Adaptimmune Therapeutics PLC Make?
-
How Much Are Adaptimmune Therapeutics PLC's Sales Annually?
ADAP Revenues are $60.3M -
How Much Profit Does Adaptimmune Therapeutics PLC's Make A Year?
ADAP net income is -$113.9M
Is Adaptimmune Therapeutics PLC Growing As A Company?
-
What Is Adaptimmune Therapeutics PLC's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.98% -
What Is Adaptimmune Therapeutics PLC's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Adaptimmune Therapeutics PLC Stock Price Performance
-
Did Adaptimmune Therapeutics PLC Stock Go Up Last Month?
Adaptimmune Therapeutics PLC share price went up by 18.1% last month -
Did ADAP's Share Price Rise Over The Last Year?
ADAP share price fell by -10.79% over the past 1 year
What Is Adaptimmune Therapeutics PLC 52-Week High & Low?
-
What Is Adaptimmune Therapeutics PLC’s 52-Week High Share Price?
Adaptimmune Therapeutics PLC has traded as high as $2.05 over the past 52 weeks -
What Is Adaptimmune Therapeutics PLC’s 52-Week Low Share Price?
Adaptimmune Therapeutics PLC has traded as low as $0.42 over the past 52 weeks
Adaptimmune Therapeutics PLC Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Adaptimmune Therapeutics PLC?
-
How Much Debt Does Adaptimmune Therapeutics PLC Have?
Total long term debt quarterly is $0 -
How Much Cash Does Adaptimmune Therapeutics PLC Have?
Cash and short term investments quarterly total is $146.9M -
What Is Adaptimmune Therapeutics PLC’s Book Value Per Share?
Book value per share is 0.17
Is Adaptimmune Therapeutics PLC Cash Flow Positive?
-
What Is ADAP Cash Flow From Operations?
Cash flow from operations (TTM) is -$140.9M -
What Is Adaptimmune Therapeutics PLC’s Cash Flow From Financing?
Cash flow from financing (TTM) is $880K -
What Is Adaptimmune Therapeutics PLC’s Cash Flow From Investing?
Cash flow from investing (TTM) is $176.5M
Adaptimmune Therapeutics PLC Return On Invested Capital
-
Is Management Doing A Good Job?
ADAP return on invested capital is -135.55% -
What Is Adaptimmune Therapeutics PLC Return On Assets?
ROA measures how assets are converting to revenues and is -36.99% -
What Is ADAP Return On Equity?
ROE is a measure of profitability and is -135.55%
Adaptimmune Therapeutics PLC Earnings Date & Stock Price
-
What Is Adaptimmune Therapeutics PLC's Stock Price Today?
A single share of ADAP can be purchased today for 1.24 -
What Is Adaptimmune Therapeutics PLC’s Stock Symbol?
Adaptimmune Therapeutics PLC trades on the nasdaq under the ticker symbol: ADAP -
When Is Adaptimmune Therapeutics PLC’s Next Earnings Date?
The next quarterly earnings date for Adaptimmune Therapeutics PLC is scheduled on August 9, 2024 -
When Is ADAP's next ex-dividend date?
Adaptimmune Therapeutics PLC's next ex-dividend date is May 17, 2024 -
How To Buy Adaptimmune Therapeutics PLC Stock?
You can buy Adaptimmune Therapeutics PLC shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Adaptimmune Therapeutics PLC Competitors
-
Who Are Adaptimmune Therapeutics PLC's Competitors?
Below is a list of companies who compete with Adaptimmune Therapeutics PLC or are related in some way:
Adaptimmune Therapeutics PLC Dividend Yield
Data Unavailable
Adaptimmune Therapeutics PLC Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | -44.58% |
Revenue: | -97.91% | -99.11% |
Analyst Recommendations
Buy Recommendations: | 4 |
---|---|
Hold Recommendations: | 2 |
Sell Recommendations: | 0 |
Price Target: | 3.50 |
Upside from Last Price: | 182.26% |